avastin
Scotland ‘no’ to Avastin
October 9, 2012Sales and Marketing NICE, Roche, Scotland, avastin
Roche has slammed the Scottish Medicines Consortium (SMC)’s decision not to recommend Avastin for women with advanced ovarian cancer in …
Sanofi’s Zaltrap data published
October 8, 2012Research and Development, Sales and Marketing Erbitux, Sanofi, Stivarga, Zaltrap, avastin
Detailed data from the Phase III trial of Sanofi’s newly-licenced anti-VEGF cancer drug Zaltrap, co-marketed with Regeneron, has been published. …
NICE does Lucentis U-turn
October 5, 2012Sales and Marketing Lucentis, NICE, Novartis, Roche, avastin
NICE has done a U-turn over its previous verdict on Novartis’ Lucentis, now recommending the drug in draft guidance to …
FDA approves Bayer’s Stivarga
October 1, 2012Research and Development, Sales and Marketing Bayer, FDA, KRAS, Roche, Stivarga, avastin
The FDA has approved Bayer HealthCare’s oncology pill Stivarga to treat patients with metastatic colorectal cancer (mCRC) whose disease has …
Lilly suffers late-stage cancer blow
September 10, 2012Research and Development, Sales and Marketing Alimta, Cancer, avastin, lilly, oncology
Eli Lilly suffered a blow to its oncology programme when a new combination treatment failed to improve overall survival in …
Another NICE no for Avastin in breast cancer
August 22, 2012Sales and Marketing NICE, avastin, breast cancer, rejection
Roche’s Avastin has been rejected once again for use in breast cancer patients. NICE has now issued final guidance saying …
New Avastin data could be bad news for Lucentis
August 14, 2012Research and Development, Sales and Marketing DMO, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD
The day after Novartis gained a new US licence for Lucentis to treat diabetic macular oedema, new data was published …
Avastin sees success in brain cancer trial
August 13, 2012Research and Development, Sales and Marketing R&D, avastin, brain cancer
A late-stage study has shown that Roche’s oncology drug Avastin, when added to standard therapy, can help people with brain …
Torisel-Avastin combo fails in kidney cancer
August 13, 2012Research and Development, Sales and Marketing R&D, Sutent, Torisel, avastin, failure, rcc
Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to …
Lucentis gains new licence in the US
August 13, 2012Sales and Marketing Eylea, FDA, Lucentis, approval, avastin, wet AMD
Roche’s eye drug Lucentis has gained a new licence in the US to treat diabetic macular oedema. The FDA has …
Lucentis price cut ends PCT-Novartis dispute
July 26, 2012Sales and Marketing ABPI, NHS, PCTs, Roche, SHIP Cluster, avastin
An NHS body has been persuaded to reverse its policy of recommending Avastin for wet AMD. The Southampton, Hampshire, Isle …
Microneedles could transform delivery of drugs to the eye
July 24, 2012Manufacturing and Production, Research and Development AMD, avastin, microneedles
Researchers in the US have demonstrated for the first time that drugs can be successfully delivered to the eye using …
NICE no for Avastin in breast cancer
July 6, 2012Sales and Marketing NICE, Roche, avastin, breast cancer, rejection
NICE has decided once again not to recommend Roche’s Avastin on the NHS for the first line treatment of metastatic …
Genentech taken to task over Avastin production
May 15, 2012Manufacturing and Production Genentech, Phil Taylor, avastin, manufacturing
FDA inspections of a manufacturing facility for Roche/Genentech’s cancer drug Avastin (bevacizumab) uncovered a number of deficiencies which could increase …
Novartis ponders Lucentis price cut in UK
May 8, 2012Medical Communications, Sales and Marketing Lucentis, NICE, avastin, market access
Novartis could cut the price of its eye drug Lucentis in the UK to head off moves to switch patients …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
